

## POST OPERATIVE STEVEN JOHNSON TYPE REACTION SECONDARY TO PIPERACILLIN

Anam Liaquat, Muhammad Waseem, Muhammad Asad

Armed Forces Institute of Cardiology/National University of Heart Diseases (NIHD)/National University of Medical Sciences (NUMS)  
Rawalpindi Pakistan

### ABSTRACT

Toxic epidermal necrolysis (TEN) and Stevens–Johnson syndrome (SJS) are lethal cutaneous reactions to medications stirring 1–2 per million individuals every year. Erythema and tenderness including blistering of both the skin and mucus membranes are common features. We report a case of Stevens–Johnson syndrome associated to piperacillin-tazobactam treatment, which is a rare phenomenon in postoperative patients.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### INTRODUCTION

Stevens–Johnson syndrome (SJS) is an acute mucocutaneous process and it is one of the manifestations of severe form of cutaneous eruptions of the skin and mucosal membrane, characterized by severe stomatitis, extensive mucosal necrosis, purulent conjunctivitis and purpuric macules. Evidently, the etiology is believed to be triggered by a number of potential etiologic agents and generally associated with the use of drugs. Here, is a case of SJS-type reaction secondary to piperacillin in surgical ICU at AFIC/NIHD.

### CASE REPORT

A 46 years old female c/o severe aortic stenosis (AS) and severe mitral stenosis (MS) was operated for DVR (mechanical mitral and aortic). At her zero post-operative day she was shifted to surgical ICU and was given first line antibiotics i.e. linezolid, meropenem and vancomycin till post-operative day one. At second post-operative day meropenem and linezolid was stopped and piperacillin/sulbactam 4.5 g IV 6 hourly was initiated and continued till post-operative day six. Patient developed large tense blisters spreading over the body including chest, abdomen and both lower limbs, along with erosion over back of trunk, buttock area and genitalia with the involvement of erythematous rash. At her fifth post-operative day oral mucosal vascular lesions

appears over tongue, buccal mucosa with encrusted lips (figure). Piperacillin was then stopped due to suspicion of exacerbation of skin reaction and cefoperazone was started. At her seventh post-operative day the patient was shifted to




Figure: (a) Oral mucosal lesions, (b) Purplish rash on upper extremities (c) Fading lesions over lower limbs.

HDU and dermatological review was taken. Vanco-mycin was stopped due to concern of SJS. She had been taking all of her other medications (tramadol, captopril, sildenafil, digoxin, warfarin, ranitidine, spiranolactone, trimetazaine, magnesium-sulphate, adrenaline) from the beginning of her post-operative day 0. By history and clinical examination, the patient was diagnosed as a case of SJS involving five percent body surface area. Piperacillin was suspected as the causative agent of the mucosal skin reaction of the patient. The patient was managed aggressively with steroids, anti-histamines, local treatment of lesions with dry sterile dressings.

### DISCUSSION

Steven Johnson syndrome (SJS) or Toxic epidermal necrolysis (TEN) is one of the cutaneous adverse drug reactions associated with

Correspondence: Dr Anum Liaquat, Department of Cardiology, Armed Forces Institute of Cardiology, Rawalpindi Pakistan  
Email: dranum68@gmail.com

eruptions of the skin and mucous membrane that can be potentially fatal. They are defined by the percentage of skin detachment on the body surface area: SJS refers to removal of epidermal layer when less than 10% of the body surface area is affected, whereas TEN refers to cases in which epidermal detachment accounts for more than 30% of the body surface area<sup>1</sup>. Affirmation involving oral, genital or ocular mucosa increases the suspicion of SJS or TEN which usually accounts in >90% of patients<sup>2</sup>.

Although the exact etiology of SJS/TEN is not fully understood, it is believed to be an immune-mediated hypersensitivity reaction in which cytotoxic T lymphocytes play a role in the pathogenesis<sup>3</sup>. In both conditions, there is an event of acute mucocutaneous rash associated with the formation of vesicles and blisters. In extreme cases they are characterized by extensive skin lesions associated with extensive necrosis and detachment of the epidermis and erosion of mucous membranes.

Various medications have been identified as culprit agents triggering SJS and TEN. Short time use of medications such as trimethoprim-sulfa-methoxazole and other sulfonamides, aminopenillins, cephalosporins, quinolones, and chloramphenicol and longterm use of medications such as carbamazepine, phenytoin, phenobarbital, valproic acid, NSAIDs (oxycamtype), nevirapine, lamotrigine, sertraline, and allopurinol are associated with the syndrome. Medications linked

with the long term use, SJS/TEN usually occurs within two months after initiating the treatment<sup>4</sup>. On the other hand, mycoplasma pneumoniae and HSV have also been linked to the occurrence of these diseases without any medication exposure<sup>5</sup>. Some case reports have been published on post-operative SJS-TEN secondary to piperacillin and tazobactam<sup>6</sup>. Beta-lactam group of antimicrobials are frequently associated with severe cutaneous adverse drug reaction CADR like SJS and TEN. Although these CADR are predominantly mild in nature, they can be at times, severe in manifestation.

### CONFLICT OF INTEREST

This study has no conflict of interest state by any author.

### REFERENCES

1. Sukasem C, Katsila T, Tempark T, Patrinos GP, Chantratita W. Drug-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Call for Optimum Patient Stratification and Therapeutics via Pharmacogenomics. *Annual Review of Genomics And Human Genetics* 2018; 1(1): 1-3.
2. Wong A, Malvestiti AA, Hafner FS. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review. *Revista da Associação Médica Brasileira* 2016; 62(1): 468-73.
3. Laurencin CT, Horan RF, Senatus PB, Wheeler CB, Lipson SJ. Stevens-Johnson-Type Reaction with Vancomycin Treatment. *Annals of Pharmacotherapy* 1992; 26(12): 1520-21.
4. Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. *Orphanet J Rare Dis* 2010; 5: 39.
5. Schneider JA, Cohen PR. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Concise Review with a Comprehensive Summary of Therapeutic Interventions Emphasizing Supportive Measures. *Advances in Therapy* 2017; 34(6): 1235-44.
6. Shah MM, Larson K, Kundu N, Walsh RM. Postoperative Stevens - Johnson syndrome secondary to piperacillin-tazobactam: A case report. *Int J Case Reports Images* 2013; 4(6): 316-20.